{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:44:19Z","timestamp":1777891459631,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,3]],"date-time":"2019-02-03T00:00:00Z","timestamp":1549152000000},"content-version":"am","delay-in-days":339,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Cancer Institute Midcareer Investigator Award in Patient-Oriented Research","award":["K24CA201543-01"],"award-info":[{"award-number":["K24CA201543-01"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R2C2CA148394-010"],"award-info":[{"award-number":["1R2C2CA148394-010"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.lungcan.2018.01.010","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T06:53:36Z","timestamp":1517640816000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"117","author":[{"given":"David E.","family":"Gerber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Socinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lecia V.","family":"Sequist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel P.","family":"Rosovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogerio C.","family":"Lilenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno R.","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Hesketh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepa S.","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin F.","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Kazakin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan H.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2018.01.010_bib0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cllc.2012.09.007","article-title":"KRAS mutations in lung cancer","volume":"14","author":"Karachaliou","year":"2013","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.01.010_bib0010","first-page":"2665","article-title":"Clinical significance of ras oncogene activation in human lung cancer","volume":"52","author":"Rodenhuis","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0015","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lungcan.2018.01.010_bib0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/anie.201307387","article-title":"Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor","volume":"53","author":"Lim","year":"2013","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0025","doi-asserted-by":"crossref","first-page":"41718","DOI":"10.1074\/jbc.M305733200","article-title":"High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors","volume":"278","author":"Fiordalisi","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","article-title":"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study","volume":"14","author":"Janne","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5732\/cjc.012.10098","article-title":"The genetics and biology of KRAS in lung cancer","volume":"32","author":"Westcott","year":"2013","journal-title":"Chin. J. cancer"},{"key":"10.1016\/j.lungcan.2018.01.010_bib0040","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0045","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1073\/pnas.94.2.701","article-title":"Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor\/scatter factor","volume":"94","author":"Takayama","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0050","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/annonc\/mdn635","article-title":"MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients","volume":"20","author":"Cappuzzo","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0055","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2018.01.010_bib0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2018.01.010_bib0065","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2011.06.004","article-title":"Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients","volume":"75","author":"Tanaka","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.01.010_bib0075","first-page":"393","article-title":"Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo","volume":"1","author":"Long","year":"2003","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0080","doi-asserted-by":"crossref","first-page":"18926","DOI":"10.1074\/jbc.272.30.18926","article-title":"A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells","volume":"272","author":"Gangarosa","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0085","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0016-5085(99)70449-X","article-title":"Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor-related peptides","volume":"117","author":"Sizemore","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lungcan.2018.01.010_bib0090","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1158\/1078-0432.CCR-09-0089","article-title":"EGFR\/KRAS\/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases","volume":"15","author":"Schmid","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0095","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-09-1173","article-title":"ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity","volume":"9","author":"Munshi","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0100","first-page":"7345","article-title":"A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo","volume":"63","author":"Christensen","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0105","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1158\/1078-0432.CCR-11-1002","article-title":"A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors","volume":"17","author":"Rosen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0110","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1002\/cncr.27575","article-title":"Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib","volume":"118","author":"Goldman","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2018.01.010_bib0115","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1200\/JCO.2010.31.0367","article-title":"Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies","volume":"29","author":"Yap","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","article-title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study","volume":"14","author":"Santoro","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0125","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.2010.34.0570","article-title":"Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer","volume":"29","author":"Sequist","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2018.01.010_bib0135","doi-asserted-by":"crossref","first-page":"918368","DOI":"10.1155\/2012\/918368","article-title":"Adult current smoking: differences in definitions and prevalence estimates\u2013NHIS and NSDUH, 2008","volume":"2012","author":"Ryan","year":"2012","journal-title":"J. Environ. Public Health"},{"key":"10.1016\/j.lungcan.2018.01.010_bib0140","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","volume":"372","author":"Kim","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2018.01.010_bib0145","first-page":"29","article-title":"Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC)","author":"Kris","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0150","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2018.01.010_bib0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0165","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2012.47.4189","article-title":"Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer","volume":"31","author":"Spigel","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0170","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(16)00038-3","article-title":"Longitudinal adverse event assessment in oncology clinical trials: the toxicity over time (ToxT) analysis of alliance trials NCCTG N9741 and 979254","volume":"17","author":"Thanarajasingam","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jtho.2015.09.006","article-title":"Patients with advanced non-Small cell lung cancer: are research biopsies a barrier to participation in clinical trials","volume":"11","author":"Lim","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0180","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/annonc\/mdv208","article-title":"Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2018.01.010_bib0185","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.cllc.2017.04.012","article-title":"Time and effort required for tissue acquisition and submission in lung cancer clinical trials","volume":"18","author":"Garcia","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.01.010_bib0190","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1200\/JCO.2007.14.8924","article-title":"Role of KRAS and EGFR as biomarkers of response to erlotinib in national cancer institute of Canada clinical trials group study BR. 21","volume":"26","author":"Zhu","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0195","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-06-3043","article-title":"KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"13","author":"Massarelli","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0200","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/cpt.91","article-title":"ALCHEMIST: bringing genomic discovery and targeted therapies to early-stage lung cancer","volume":"97","author":"Gerber","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.lungcan.2018.01.010_bib0205","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2015.10.028","article-title":"Responses to the multitargeted MET\/ALK\/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation","volume":"90","author":"Jorge","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.01.010_bib0210","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.2015-0510","article-title":"MET exon 14 skipping in non-Small cell lung cancer","volume":"21","author":"Heist","year":"2016","journal-title":"Oncologist"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218300205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218300205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:23:03Z","timestamp":1759234983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218300205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":42,"alternative-id":["S0169500218300205"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.01.010","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}